USPTO extends BL-1020 patent rights
The patent will extend coverage period by at least until 2031, which is nine years longer than the granted patent coverage earlier to the company. The patent applications
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
The randomised, double-blind trial will compare progression-free survival in 329 post-ASCT patients receiving Adcetris to those receiving placebo. Patients receive Adcetris every three weeks for up to one